newsfilter
← Latest News
ACCESS Newswire·

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol

New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"